JP Morgan Chase’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-24
| Closed | – | – | 7343 |
|
|
2022
Q3 | $0 | Buy |
+24
| New | +$9 | ﹤0.01% | 7107 |
|
|
2022
Q1 | – | Sell |
-344
| Closed | -$1K | – | 7246 |
|
|
2021
Q4 | $1K | Buy |
+344
| New | +$1.16K | ﹤0.01% | 6590 |
|
|
2021
Q3 | – | Sell |
-57,286
| Closed | -$254K | – | 6982 |
|
|
2021
Q2 | $254K | Sell |
57,286
-184,513
| -76% | -$939K | ﹤0.01% | 5108 |
|
|
2021
Q1 | $1.76M | Sell |
241,799
-44,495
| -16% | -$366K | ﹤0.01% | 3813 |
|
|
2020
Q4 | $2.18M | Sell |
286,294
-21,313
| -7% | -$143K | ﹤0.01% | 3416 |
|
|
2020
Q3 | $2.91M | Sell |
307,607
-41,801
| -12% | -$317K | ﹤0.01% | 2971 |
|
|
2020
Q2 | $2.96M | Sell |
349,408
-58,513
| -14% | -$385K | ﹤0.01% | 2846 |
|
|
2020
Q1 | $2.01M | Buy |
407,921
+393,304
| +2,691% | +$3.06M | ﹤0.01% | 2959 |
|
|
2019
Q4 | $105K | Buy |
14,617
+11,925
| +443% | +$108K | ﹤0.01% | 4878 |
|
|
2019
Q3 | $29K | Buy |
2,692
+396
| +17% | +$4.24K | ﹤0.01% | 5330 |
|
|
2019
Q2 | $28K | Buy |
2,296
+314
| +16% | +$4.17K | ﹤0.01% | 5378 |
|
|
2019
Q1 | $20K | Sell |
1,982
-463
| -19% | -$4.31K | ﹤0.01% | 5412 |
|
|
2018
Q4 | $26K | Buy |
+2,445
| New | +$29.5K | ﹤0.01% | 5272 |
|
JP Morgan Chase's LOGC Position: Q4 2022 in Review
JP Morgan Chase sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 24 shares.
JP Morgan Chase first reported a position in LOGC in Q4 2018 and held it in 13 quarters. The position peaked at $2.96M in Q2 2020. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.
- JP Morgan Chase reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- JP Morgan Chase sold 24 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022.
- JP Morgan Chase first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 13 quarters.
- JP Morgan Chase's LogicBio Therapeutics, Inc. Common Stock position peaked at $2.96M in Q2 2020.
- 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.
Based on JP Morgan Chase's 13F filing for Q4 2022, filed 13 Feb 2023.